RJA
LOGC

Raymond James & Associates’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

Raymond James & Associates’s Portfolio LOGC Stock Details LOGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-10,474
Closed -$76K – 4258
2021
Q1 		$76K Buy
+10,474
New +$86.2K ﹤0.01% 3814

Other funds holding LOGC

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Raymond James & Associates's LOGC Position: Q2 2021 in Review

Raymond James & Associates sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q2 2021, closing a stake of 10,474 shares — an estimated $76K sold.

Raymond James & Associates first reported a position in LOGC in Q1 2021 and held it in 1 quarter. The position peaked at $76K in Q1 2021. 63 funds tracked by Wall St. Rank hold LOGC as of Q2 2021.

  • Raymond James & Associates reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Raymond James & Associates sold 10,474 LogicBio Therapeutics, Inc. Common Stock shares in Q2 2021, an estimated $76K.
  • Raymond James & Associates first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q1 2021 and held it in 1 quarter.
  • Raymond James & Associates's LogicBio Therapeutics, Inc. Common Stock position peaked at $76K in Q1 2021.
  • 63 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q2 2021.

Based on Raymond James & Associates's 13F filing for Q2 2021, filed 11 Aug 2021.